Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam perioperative management for general anesthesia
ChiCTR2200064255Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: cognitive impairment. Started Oct 2022; status: recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2200064255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064255.